Visual storytelling for medical publications
2022-08-22 17:05
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial
Addition of
#elotuzumab
to pomalidomide and dexamethasone led to one additional year of survival in patients with relapsed or refractory multiple
#myeloma
.
https://bit.ly/3QOFf8d
#VisualAbstract
#in
#hematology
@mdwrtcom